Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.46 |
| ▸ | SMO | Q99835 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KAT6A | Q92794 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7078520 | 0.87 | ALDH1A1 (0.53) | MEN1KMT2ASMN1; SMN2TSHRHPGD | |
| SCHEMBL7080254 | 0.86 | MEN1 (0.47) | MEN1KMT2ASMN1; SMN2KAT6ATSHR | |
| SCHEMBL7083338 | 0.84 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2KAT6ATSHR | |
| SCHEMBL7081565 | 0.83 | USP2 (0.47) | MEN1KMT2ASMN1; SMN2KAT6ATSHR | |
| SCHEMBL7077439 | 0.83 | ALDH1A1 (0.44) | MEN1KMT2ASMN1; SMN2KAT6ATSHR | |
| SCHEMBL7080300 | 0.83 | ALDH1A1 (0.48) | MEN1KMT2ASMN1; SMN2KAT6ALMNA | |
| SCHEMBL7083205 | 0.82 | ALDH1A1 (0.52) | MEN1KMT2ASMN1; SMN2KAT6ATSHR | |
| SCHEMBL7077442 | 0.81 | SMPD1 (0.55) | MEN1KMT2AKAT6ATP53 | |
| SCHEMBL7047672 | 0.81 | SMPD1 (0.55) | MEN1KMT2AKAT6ATP53 | |
| SCHEMBL7050498 | 0.81 | SMPD1 (0.52) | MEN1KMT2ASMN1; SMN2KAT6ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162818-A1 | Acylsulfonamide derivative | AJINOMOTO CO. INC. (JP) | 2003-08-28 | — | — | US | disclosed |
| US-6555584-B1 | Acetyl-coa carboxylase inhibitors | AJINOMOTO CO., INC. (JP) | 2003-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162818-A1 | Acylsulfonamide derivative | ACSS2, ACACA, FASN | MEN1 4502/4885KMT2A 934/4885GPR132 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.